Table 4 Clinicopathological and prognostic difference among 21 rheumatoid arthritis (RA) patients with other iatrogenic immunodeficiency-associated (OIIA) T- and NK-cell lymphoproliferative disorders (TNK-LPDs), 39 with OIIA B-LPDs and 22 with non-OIIA B-LPDs

No. of patients

21

39

22

nt

nt

Age, years, median

64

67

68

0.438

0.108

Sex, female: male

15:6

32:07:00

19:3

0.532

0.281

Nodal: extranodal

13:8

14:25

8:14

0.097

0.131

RA duration, median (months)

72

166

177

0.008

0.0007

MTX therapy

21 (100%)

38 (97%)

0

1

nt

MTX duration, median (months)

53

67

0

0.194

nt

Biologic drugs

4 (19%)

8 (21%)

0

0.84

0.042

LDH, median (U/L)

584

417.2

673

0.105

0.91

LDH ≥ 300 U/L

13 (62%)

13/33 (39%)

14 (64%)

0.182

0.843

sIL2R, median (U/ml)

7588

1623

5731

0.072

0.289

sIL2R ≥ 2000 U/ml

10/19 (53%)

6/28 (21%)

11/16 (69%)

0.025

0.533

Stages III and IV

16 (76%)

17 (44%)

12 (57%)

0.032

0.52

Regression of LPDs^a

12 (57%)

15 (38%)

0

0.265

nt

CD30 ≥ 30%

7 (33%)

22 (56%)

3 (13%)

0.151

0.162

p53 ≥ 50%

8 (38%)

17/29 (59%)

9/14 (64%)

0.25

0.176

CMYC ≥ 50%

5 (24%)

7/29 (24%)

6/13 (46%)

0.757

0.262

EBER+ atypical lymphocytes ≥ 50%

5 (24%)

21 (54%)

1 (4%)

0.031

0.185

EBV latency infection patterns I/II/III

1/4/0

0/17/4

0/1/0

0.002

0.178

EBER+ atypical and reactive lymphocytes

15 (71%)

27 (69%)

3 (14%)

0.91

0.0002

Chemotherapies

8 (38%)

20 (51%)

20 (91%)

0.743

0.0004

Five-year survival

57%

68%

40%

0.083

0.234